Literature DB >> 6807042

Neurofibromatosis. A clinical and genetic study of 96 cases in Gothenburg, Sweden.

B Samuelsson, R Axelsson.   

Abstract

Ninety-six persons, living in Gothenburg, Sweden, on the first of January 1978 and known by the health services as cases of neurofibromatosis, were investigated concerning clinical and genetic aspects of the disease. Close relatives were also interviewed and examined. The diagnostic criteria were operationally defined according to number of café-au-lait spots and/or neurofibromas. The prevalence of neurofibromatosis was estimated to be 0.02%. The following findings were made in the patients: axillary freckling (48%), neurological symptoms (30%), epilepsy (3-9%), sarcoma (4%), pheochromocytoma (3%), osseous dysplasias (12%), subnormal intelligence (45%) and psychiatric symptoms (33%). The genetic analysis revealed a dominantly inherited disease with full penetrance and a very high mutation frequency, at least 4.3 X 10(-5). Questions commonly encountered during counselling are discussed.

Entities:  

Mesh:

Year:  1981        PMID: 6807042

Source DB:  PubMed          Journal:  Acta Derm Venereol Suppl (Stockh)        ISSN: 0365-8341


  12 in total

1.  Neurofibromatosis-1: a maximum likelihood estimation of mutation rate.

Authors:  M Clementi; G Barbujani; L Turolla; R Tenconi
Journal:  Hum Genet       Date:  1990-01       Impact factor: 4.132

2.  Ophthalmic manifestations of neurofibromatosis.

Authors:  S Huson; D Jones; L Beck
Journal:  Br J Ophthalmol       Date:  1987-03       Impact factor: 4.638

3.  A genetic study of von Recklinghausen neurofibromatosis in south east Wales. I. Prevalence, fitness, mutation rate, and effect of parental transmission on severity.

Authors:  S M Huson; D A Compston; P Clark; P S Harper
Journal:  J Med Genet       Date:  1989-11       Impact factor: 6.318

4.  A clinical study of type 1 neurofibromatosis in north west England.

Authors:  J M McGaughran; D I Harris; D Donnai; D Teare; R MacLeod; R Westerbeek; H Kingston; M Super; R Harris; D G Evans
Journal:  J Med Genet       Date:  1999-03       Impact factor: 6.318

5.  The Impact of Neurofibromatosis Type 1 on the Health and Wellbeing of Australian Adults.

Authors:  Hilda A Crawford; Belinda Barton; Meredith J Wilson; Yemima Berman; Valerie J McKelvey-Martin; Patrick J Morrison; Kathryn N North
Journal:  J Genet Couns       Date:  2015-04-19       Impact factor: 2.537

6.  Neurofibromatosis type 1 in children.

Authors:  G R Beauchamp
Journal:  Trans Am Ophthalmol Soc       Date:  1995

Review 7.  Psychological aspects of von Recklinghausen neurofibromatosis (NF1)

Authors:  S E Mouridsen; S A Sørensen
Journal:  J Med Genet       Date:  1995-12       Impact factor: 6.318

8.  Neurofibromatosis type 1 in Israel: survey of young adults.

Authors:  B Z Garty; A Laor; Y L Danon
Journal:  J Med Genet       Date:  1994-11       Impact factor: 6.318

9.  Screening for Hereditary Pheochromocytoma in a Patient with Neurofibromatosis Type 1: A Case Report.

Authors:  Inês Isabel Ferreira Barros; Fernando Manso; Ana Isabel Caldas E Silva; Maria Ramires Silva Lopes Pereira
Journal:  touchREV Endocrinol       Date:  2021-04-28

10.  Somatic neurofibromatosis type 1 (NF1) inactivation characterizes NF1-associated pilocytic astrocytoma.

Authors:  David H Gutmann; Michael D McLellan; Ibrahim Hussain; John W Wallis; Lucinda L Fulton; Robert S Fulton; Vincent Magrini; Ryan Demeter; Todd Wylie; Cyriac Kandoth; Jeffrey R Leonard; Abhijit Guha; Christopher A Miller; Li Ding; Elaine R Mardis
Journal:  Genome Res       Date:  2012-12-05       Impact factor: 9.043

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.